Skip to main content
Premium Trial:

Request an Annual Quote

Astex to Merge with MetaGen Pharma

NEW YORK, Oct. 31 (GenomeWeb News) - Astex of Cambridge, UK announced today that it will merge with Berlin-based metaGen Pharmaceuticals.

 

Under the terms of the agreement, Astex will acquire all of metaGen's shares, and existing shareholders in metaGen will become shareholders in Astex. Astex said that metaGen will be consolidated into its Cambridge facilities, and that metaGen's capabilities will be used in cancer research.

 

"The opportunity to merge with metaGen was compelling given that it provides Astex with the key assets to fuel the next stage of our growth including cancer drug development capabilities and a broader cash basis. In addition, it builds on our existing relationship with Schering," Astex CEO Timothy Haines said in a statement.

 

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.